In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed:  1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. <a href="https://pubmed.ncbi.nlm.nih.gov/38820078/">https://pubmed.ncbi.nlm.nih.gov/38820078/</a> 2. 5-year follow-up of ENESTnd RCT (nilotinib): <a href="https://pubmed.ncbi.nlm.nih.gov/26837842/">https://pubmed.ncbi.nlm.nih.gov/26837842/</a> 3. 10-year follow-up of ENESTnd RCT (nilotinib): <a href="https://pubmed.ncbi.nlm.nih.gov/33414482/">https://pubmed.ncbi.nlm.nih.gov/33414482/</a> 4. 10-year follow-up of CML-IV RCT (imatinib): <a href="https://pubmed.ncbi.nlm.nih.gov/25676422/">https://pubmed.ncbi.nlm.nih.gov/25676422/</a> 5. MD Anderson data on low-dose dasatinib (50 mg): <a href="https://pubmed.ncbi.nlm.nih.gov/36054032/">https://pubmed.ncbi.nlm.nih.gov/36054032/</a><a href="https://pubmed.ncbi.nlm.nih.gov/31553487/">https://pubmed.ncbi.nlm.nih.gov/31553487/</a> 6. CML: 2025 update on diagnosis, therapy, and monitoring: <a href="https://pubmed.ncbi.nlm.nih.gov/39093014/">https://pubmed.ncbi.nlm.nih.gov/39093014/</a>

<description>
 &lt;p&gt;In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: &lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/38820078/"&gt;https://pubmed.ncbi.nlm.nih.gov/38820078/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;2. 5-year follow-up of ENESTnd RCT (nilotinib): &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/26837842/"&gt;https://pubmed.ncbi.nlm.nih.gov/26837842/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;3. 10-year follow-up of ENESTnd RCT (nilotinib): &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/33414482/"&gt;https://pubmed.ncbi.nlm.nih.gov/33414482/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;4. 10-year follow-up of CML-IV RCT (imatinib): &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/25676422/"&gt;https://pubmed.ncbi.nlm.nih.gov/25676422/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;5. MD Anderson data on low-dose dasatinib (50 mg): &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/36054032/"&gt;https://pubmed.ncbi.nlm.nih.gov/36054032/&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/31553487/"&gt;https://pubmed.ncbi.nlm.nih.gov/31553487/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;6. CML: 2025 update on diagnosis, therapy, and monitoring: &lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/39093014/"&gt;https://pubmed.ncbi.nlm.nih.gov/39093014/&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;
 </description>

Blood Cancer Talks

Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian

Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian

Description